Morgan Stanley Pds Biotechnology Corp Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PDSB
# of Institutions
64Shares Held
4.32MCall Options Held
253KPut Options Held
70.4K-
Vanguard Group Inc Valley Forge, PA1.52MShares$3.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$1.06 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA415KShares$900,7950.0% of portfolio
-
Inspirion Wealth Advisors, LLC344KShares$747,3340.18% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny234KShares$508,2330.0% of portfolio
About PDS Biotechnology Corp
- Ticker PDSB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,458,700
- Market Cap $61.8M
- Description
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...